ARPI, Inc. appears in FDA records as the applicant for K260436, a Traditional 510(k) received on February 11, 2026 and decided on November 6, 2026 with decision code SESE, meaning substantially equivalent. The record lists the device as ECG Buddy-LVD (EB-LVD-01) under product code QYE, advisory committee CV, device class 2, regulation number 870.2380, with a Summary statement. The openFDA device name field reads "Reduced Ejection Fraction Machine Learning-Based Notification Software." The filing address is in Seongnam-Si, Korea, and the applicant contact is listed as Yoonho Song. The company's own announcement describes the clearance as its first US regulatory clearance and states that its ECG analysis technology is already cleared in Korea, the EU, Australia, Taiwan, Saudi Arabia and other markets. [1][4][5]
The cleared device and its stated scope
The FDA record identifies ECG Buddy-LVD as a machine learning-based notification software device for reduced ejection fraction, classified as class 2 cardiovascular software. ARPI's announcement states that the product analyzes a standard 12-lead ECG to aid clinicians in screening for a left ventricular ejection fraction of 40% or less, and that the FDA determined it substantially equivalent under the 510(k) premarket notification process on November 6, 2026. The clearance type is Traditional, the third-party review flag is N, and the review advisory committee is Cardiovascular. [1][5]
ARPI's product documentation for ECG Buddy-LVD sets input conditions for the ECG Buddy line: analysis is limited to 12-lead ECGs acquired on medical-grade ECG devices at 25 mm/sec speed and 10 mm/mV scale, with a visible grid on the printout or image. Recordings made with modified lead placements, such as reverse or posterior leads, and images distorted vertically or horizontally are described as not analyzable. The same page carried a "FDA clearance pending" label at the time it was captured. [2]
Other documented products and Korean clearances
ARPI’s website describes ECG Buddy as software as a medical device that captures and analyzes 12-lead electrocardiograms. The company states that its output includes 10 digital biomarkers and classification of 11 heart rhythms. The site lists product license number 24-1179 with an initial approval date of January 9, 2024, and states that a mobile version can be downloaded for iOS and Android. These are the publisher’s product descriptions, rather than independent clinical results. [7]
A separate product line, ECG Buddy Clinic, is described by ARPI as screening for asymptomatic LV dysfunction, PAF and other conditions through five cardiovascular biomarker risk scores for clinic and outpatient care, and is labeled an MFDS-certified Class III medical device. The same page labels ECG Buddy an MFDS-certified Class II medical device. These are the manufacturer's own statements about Korean certification, not FDA determinations. [6]
Company identity and published footprint
ARPI describes itself as a medical AI company specializing in electrocardiogram analysis, with a stated mission to build AI that helps clinicians. The company lists Joonghee Kim as CEO and gives a contact address at Kins Tower Suite 1401, 8 Seongnam-daero 331beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, with telephone and email contacts. That address matches the location in the FDA filing record; the filing address is not treated here as a verified headquarters designation. [1][4][8]
ARPI's announcement states that its ECG analysis technology is used by more than 150 Korean hospitals, while a company homepage section states that its products are used daily in more than 120 hospitals. Both figures are company-published and are not reconciled in the available documents. ARPI states that it is engaging US health systems and partners on adoption of ECG Buddy-LVD following the clearance. [4][6]
What the filing record shows
The linked FDA collection for this company contains one 510(k) record, K260436, with a decision of SESE; the sample of linked records is the same single entry. These counts describe the filings retrieved as of the snapshot date and do not represent total company sales, total portfolio or safety performance. No recall records appear in the retrieved sample. [1]

